HSP90B2P and glioblastoma: Recent randomized clinical trials of vaccination with autologous tumor-derived HSP-peptide complex have been shown to improve survival in patients with newly diagnosed and recurrent glioblastoma (Crane et al., 2013; Bloch et al., 2014; Ji et al., 2018).